You are here Home Resources and guidance Sponsors TudorRose Consulting Pty Ltd Regulatory activities for this sponsor. Listen Print Share LinkedIn (Twitter) Facebook Email Loading... Type Designation or determination (2) Australian public assessment report (AusPar) (1) Prescription medicine decision summary (1) Prescription medicine registration (1) Date 2020 (3) 2019 (2) Search Sponsor content5 result(s) found, displaying 1 to 5 AusPAR: Ripretinib 30 November 2020 Australian public assessment report (AusPar) Australian Public Assessment Report for Ripretinib Qinlock 21 July 2020 Prescription medicine decision summary Australian prescription medicine decision summary QINLOCK (Tudorrose Consulting Pty Ltd) 10 July 2020 Prescription medicine registration Active ingredients: ripretinib. Notice for ripretinib (Tudorrose Consulting Pty Ltd) 4 December 2019 Designation or determination Priority review Notice for ripretinib (Tudorrose Consulting Pty Ltd) 4 December 2019 Designation or determination Orphan drug
AusPAR: Ripretinib 30 November 2020 Australian public assessment report (AusPar) Australian Public Assessment Report for Ripretinib
Qinlock 21 July 2020 Prescription medicine decision summary Australian prescription medicine decision summary
QINLOCK (Tudorrose Consulting Pty Ltd) 10 July 2020 Prescription medicine registration Active ingredients: ripretinib.
Notice for ripretinib (Tudorrose Consulting Pty Ltd) 4 December 2019 Designation or determination Priority review
Notice for ripretinib (Tudorrose Consulting Pty Ltd) 4 December 2019 Designation or determination Orphan drug